- Home
- GNW vs RYTM Comparison
GNW vs RYTM Comparison
Compare GNW & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNW
- RYTM
- Stock Information
- Founded
- GNW 1871
- RYTM 2008
- Country
- GNW United States
- RYTM United States
- Employees
- GNW N/A
- RYTM N/A
- Industry
- GNW Life Insurance
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- GNW Finance
- RYTM Health Care
- Exchange
- GNW Nasdaq
- RYTM Nasdaq
- Market Cap
- GNW 3.2B
- RYTM 3.5B
- IPO Year
- GNW 2004
- RYTM 2017
- Fundamental
- Price
- GNW $6.52
- RYTM $56.07
- Analyst Decision
- GNW Hold
- RYTM Strong Buy
- Analyst Count
- GNW 1
- RYTM 10
- Target Price
- GNW $7.00
- RYTM $66.90
- AVG Volume (30 Days)
- GNW 4.7M
- RYTM 380.5K
- Earning Date
- GNW 02-18-2025
- RYTM 02-26-2025
- Dividend Yield
- GNW N/A
- RYTM N/A
- EPS Growth
- GNW 323.28
- RYTM N/A
- EPS
- GNW 0.68
- RYTM N/A
- Revenue
- GNW $7,295,000,000.00
- RYTM $112,530,000.00
- Revenue This Year
- GNW N/A
- RYTM $66.58
- Revenue Next Year
- GNW N/A
- RYTM $44.63
- P/E Ratio
- GNW $9.64
- RYTM N/A
- Revenue Growth
- GNW N/A
- RYTM 81.55
- 52 Week Low
- GNW $5.67
- RYTM $35.17
- 52 Week High
- GNW $7.90
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- GNW 27.47
- RYTM 42.18
- Support Level
- GNW $7.15
- RYTM $56.03
- Resistance Level
- GNW $7.38
- RYTM $58.65
- Average True Range (ATR)
- GNW 0.16
- RYTM 1.87
- MACD
- GNW -0.09
- RYTM -0.27
- Stochastic Oscillator
- GNW 0.00
- RYTM 5.45
About GNW Genworth Financial Inc
Genworth Financial is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. most of the revenue is generated by the Long-Term Care Insurance segment. The company earns most of its revenue in the United States.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.